Emerade Product Failing To Deliver Adrenaline
An adrenaline autoinjector used in the emergency treatment of anaphylaxis is reported to be failing to deliver a dose of adrenaline from the syringe due to blockage of the needle.
Medicines and Healthcare products Regulatory Agency (MHRA) issued a Class 4 medicine defect information alert.
There are insufficient supplies available of alternative brands to support the removal of one brand.
Emerade pens are not being recalled.
Patients should carry two (2) in-date Emerade autoinjector pens at all times.
Patients experiencing Emerade failing to activate should report via the Yellow Card Scheme.
Click to rate this post!
[Total: 0 Average: 0]
No Comments